Stocks · News reference
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
PMV Pharmaceuticals announced that updated Phase 2 results from the PYNNACLE clinical trial of rezatapopt, a p53 reactivator for TP53 Y220C-positive advanced solid tumors, will be presented at the ENA 2026 symposium on November 20, 2026. The presentation will showcase efficacy data across multiple tumor types including ovarian, lung, breast, and endometrial cancers.
Filed: 2026-10-05 AccNo: 0001193125-26-413254 Size: 161 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
PMV Pharma announced a public offering of 22.055 million shares of common stock and pre-funded warrants to purchase 19.9 million shares, along with accompanying warrants, expected to raise approximately $50.8 million gross proceeds. The offering is priced at $1.21 per share and is expected to close on or about September 2, 2026.
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of 27 cents per